# US 2020/0002685 A1 · Novel p450-bm3 variants with improved activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002685 A1
- Document ID: US20200002685A1
- Status: Published application
- Kind: A1
- Application number: 16/562,673
- Filed: 2019-09-06
- Published: 2020-01-02
- Earliest claimed: 2015-07-07
- Assignees: Codexis, Inc.
- Applicants: Codexis, Inc.
- Inventors: Robert Osborne; Vesna Mitchell; Khin Yu Naing Htwe; Xiyun Zhang; Erika M. Milczek; Jeffrey C. Moore
- Web page: https://patentgrep.com/patent/US20200002685A1

## CPC

- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 1/16: Yeasts; Culture media therefor
- C12N 1/20: Bacteria; Culture media therefor
- C12N 9/0042: {NADPH-cytochrome P450 reductase (1.6.2.4)}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Y 106/02004: NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
- C12Y 114/14001: Unspecific monooxygenase (1.14.14.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

## Claims

### Claim 1

A recombinant cytochrome P450-BM3 variant having at least 90% sequence identity to a polypeptide sequence comprising the sequence set forth in SEQ ID NOS: 6, 8, 12, 14, or 16.

### Claim 2 (depends on 1)

The recombinant cytochrome P450-BM3 variant of claim 1, wherein said variant oxidizes at least three organic substrates.

### Claim 3 (depends on 2)

The recombinant cytochrome P450-BM3 variant of claim 2, wherein said organic substrate is selected from loratadine, imatinib, geftinib, and diclofenac.

### Claim 4

A recombinant polynucleotide sequence encoding a recombinant cytochrome p450-BM3 variant having at least 90% sequence identity to a polynucleotide sequence comprising the sequence set forth in SEQ ID NO: 5, 7, 11, 13, or 15.

### Claim 5 (depends on 1)

A recombinant polynucleotide sequence encoding a recombinant cytochrome P450-BM3 variant of claim 1.

### Claim 6 (depends on 4)

The recombinant polynucleotide sequence of claim 4, wherein said sequence comprises SEQ ID NO: 5, 7, 11, 13, or 15.

### Claim 7 (depends on 4)

An expression vector comprising the polynucleotide sequence of claim 4.

### Claim 8 (depends on 7)

The vector of claim 7, wherein said polynucleotide sequence is operably linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.

### Claim 9 (depends on 8)

The vector of claim 8, wherein said host cell is a prokaryotic or eukaryotic cell.

### Claim 10 (depends on 9)

The vector of claim 9, wherein said host cell is a prokaryotic cell.

### Claim 11 (depends on 10)

The vector of claim 10, wherein said host cell is E. coli.

### Claim 12 (depends on 7)

A host cell comprising the vector of claim 7.

### Claim 13 (depends on 1)

A method for producing at least one recombinant cytochrome P450-BM3 variant comprising culturing a host cell under conditions such that at least one recombinant cytochrome P450-BM3 variant of claim 1 is produced by said host cell.

### Claim 14 (depends on 13)

The method of claim 13, further comprising the step of recovering said at least one recombinant cytochrome P450-BM3 variant.
